There are multiple psychedelics currently in late stage trials with the Federal Drug Administration (FDA) and some of the countries most prestigious medical research organizations for use in psychedelic assisted psychotherapy. MDMA, commonly referred to as ecstasy or molly, is slated for legal use with specially trained psychotherapist in 2023. Psilocybin will likely be ready for use with similarly trained psychotherapies by 2025. They each offer unique benefits in aiding with various psychological and emotional diagnosis and conundrums that bring folx into psychotherapy.
While some people eager to explore the way psychedelics might help with their psychotherapy journeys, Ketamine offers its own unique features making it an excellent medicine to consider for use as a tool for psychotherapy.
Upsides to Ketamine:
- It is currently legal and available for use in clinical settings, with the medicine itself reasonably priced, and accessible through a psychiatrist.
- It has long been established as a particularly safe drug with minimal risks and side-effects.
- The molecule itself can help with mood disorders, much like standard anti-depressants and anti-anxieties, but operating of a different system (glutamate).
- The medicine facilitates neuroplasticity for days after each treatment, meaning it helps the mind to operate outside of our default mode functioning, creating novel opportunities for growth and change with our most entrenched thoughts and behaviors.
- The trip itself only lasts 40 to 60 minutes, which makes it ideal for first time psychedelic users, allows the trip to be focused on a handful of thoughts/feelings/experiences, making it easier to harness/capture them for processing, and also lends itself well to having a therapist present during the experience.